











































Active HCV Replication but Not HCV or CMV Seropositive
Status Is Associated With Incident and Prevalent Type 2
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Objective: To analyze the association between chronic hepatitis C
virus (HCV) and cytomegalovirus (CMV) infections with type 2
diabetes in HIV-infected patients.
Methods: HIV-1-infected patients enrolled in ICONA, a prospec-
tive cohort study involving 42 tertiary care centers in Italy, were
selected with the following characteristics: for the diabetes incidence
analysis, all patients with available CMV IgG results (first available
test = baseline) and without type 2 diabetes were followed until onset
of type 2 diabetes, last available clinical follow-up, death or September
30, 2014, whichever occurred first; for the prevalence analysis, all
ICONA patients were analyzed at their last follow-up visit. Main
outcome measures were the new onset of type 2 diabetes (incidence
analysis) and the prevalence of type 2 diabetes at last follow-up.
Results: During 38,062 person-years of follow-up (PYFU) in 6505
individuals, we observed 140 cases of incident type 2 diabetes
(Incidence rate 3.7, 95% CI: 3.1 to 4.3, per 1000 PYFU). In
a multivariable Poisson regression model, HCV-antibody (Ab)
+/HCV RNA+ patients [adjusted relative rate versus HCV-Ab negative
1.73 (95% CI: 1.08 to 2.78)] but not HCV Ab+RNA2 or CMV IgG+
patients, had a higher risk of diabetes. Among 12,001 patients, 306
(2.5%) prevalent cases of type 2 diabetes were detected. HCV Ab
+RNA+ status was independently associated with prevalent diabetes
(adjusted Odds Ratio vs HCV Ab2 2.49; 95% CI: 1.08 to 5.74),
whereas HCV-Ab+/HCV RNA2 and CMV IgG+ status were not.
Conclusion: In HIV-infected individuals, active HCV replication
but not prior HCV exposure or latent CMV infection is associated
with incident and prevalent type 2 diabetes.
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INTRODUCTION
Antiretroviral therapy has significantly reduced HIV-
associated morbidity and mortality.1 However, the substan-
tially increased survival has exposed the HIV-infected
population to a relevant number of co-morbid conditions,
such as metabolic and cardiovascular disorders,2 and to the
long-term consequences of chronic co-infections, including
chronic hepatitis C virus (HCV) infection.3 Among the
metabolic disorders, type 2 diabetes affects a relevant number
of persons living with HIV. Although diabetes mellitus does
not seem more frequent in HIV-infected subjects than in
negative controls,4 in the HIV-infected population diabetes
represents a risk factor for all specific causes of death except
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non-AIDS cancers.5 Moreover, exposure to some antiretro-
viral agents may also favor the emergence of type 2
diabetes.6–8 In any case, the clinical impact of diabetes, as
a risk factor for cardiovascular and cerebrovascular disorders,
may be more relevant in the HIV-infected population where
the incidence of cardiovascular disease is already increased as
compared to the age-matched general population.2
Chronic viral infections lead to immune activation and
may therefore cause a number of co-morbidities. Indeed,
chronic HCV infection, apart from causing liver-related
morbidity and mortality, is also associated with an increased
incidence of extra-hepatic disorders, including diabetes and
cardiovascular disease, in the HIV-negative population.9,10
In HCV-infected patients, HIV co-infection has been
associated with an accelerated liver disease.3 Whether HCV
co-infection favors the emergence of diabetes in HIV-infected
patients remains to be fully established. Some reports indicate
a similar incidence of type 2 diabetes in HCV-antibody-
positive HIV-infected patients11,12 while other studies indi-
cate that HCV-antibody-positive individuals have an
increased risk.4,10 However, it is not clear whether HCV-
antibody positivity is a marker for a specific population
exposed to a higher risk of diabetes due to behavioral factors
or whether HCV infection by itself represents a risk factor for
this disorder. In addition, latent cytomegalovirus (CMV)
infection, as determined by a positive CMV-antibody seros-
tatus, has been associated with an increased incidence of non-
AIDS events, particularly cardiovascular events,13 because of
an immune activation mechanism. Latent CMV infection has
also been associated with diabetes mellitus.14
Aim of our study was to determine the impact of HCV
infection, both as prior HCV exposure and as active HCV
infection, and of latent CMV infection on the incidence and
the prevalence of type 2 diabetes in a nationally representative
Italian cohort of HIV-infected individuals.
PATIENTS AND METHODS
Patient selection for the incidence and prevalence
analysis and definition of type 2 diabetes.
For the incident type 2 diabetes analysis, patients
enrolled in the ICONA Foundation Study cohort15 were
selected who (1) had an available CMV IgG result (time of
first result = baseline) and (2) did not have diabetes at
baseline. For the prevalent type 2 diabetes analysis, all
ICONA enrollees were evaluated at the date of diabetes
diagnosis or at their last available follow-up, whichever
occurred first. Type 2 diabetes was defined by one of the
following criteria: (1) diagnosis by the treating clinician, (2)
use of antidiabetic drugs, or (3) first of 2 consecutive blood
glucose levels .125 mg/dL at a verified fasting status. All the
type 2 diabetes diagnoses were validated by an external
monitor using the above criteria.
Statistical Analysis
We used standard descriptive statistics to describe
characteristics at baseline for the population analyzed for
the diabetes incidence and at the date of diabetes diagnosis or
last available follow-up for the population analyzed for the
diabetes prevalence. Time to diagnosis of diabetes was
analyzed using the Kaplan–Meier method using the time of
first CMV serology as baseline. Patients were followed until
onset of type 2 diabetes, last available clinical follow-up,
death or September 30, 2014, whichever occurred first.
Predictors of incident type 2 diabetes were analyzed by
Poisson regression. In the multivariable model, we included
variables with P , 0.10 at univariate analysis plus CMV
serostatus. The type of antiretroviral treatment regimen used
was analyzed as time updated variable.
Factors associated with prevalent type 2 diabetes at the
last available follow-up were analyzed by logistic regression;




Six thousand five hundred five patients were suitable
for the type 2 diabetes incidence analysis. Baseline patients
characteristics are summarized in Table 1 (left part).
CMV IgG were detected in 84.4% of 6,505, HCV-
antibodies in 31.5% of 6112 tested, of whom 83.5% of 1033
tested had a detectable HCV RNA. During 38.062 person-
years of follow-up (PYFU), we observed 140 cases of incident
type 2 diabetes with an incidence rate of 3.7 (95% CI: 3.1 to
4.3) per 1.000 PYFU. Time-to-event analysis showed that the
5-years, 10-years, and 15-years estimated probability of type 2
diabetes were 1.8% (95% CI: 1.5 to 2.3), 3.4% (2.8–4.1) and
5.4% (4.4–6.7), respectively (Fig. 1). By multivariable Poisson
regression analysis (Table 2), HCV RNA-positive status, but
not HCV-antibody positive, HCV RNA negative status was
independently associated with a higher incidence of type 2
diabetes as compared to an HCV-antibody negative status
[adjusted relative rate, ARR, 1.73 (1.08–2.78)]; CMV IgG
serology was not associated with incident diabetes. Other
independent predictors of diabetes onset were male gender,
older age, a higher baseline BMI, higher baseline glucose and
triglycerides levels, presence of arterial hypertension, current
use of a regimen containing NRTIs with an unboosted protease
inhibitor (as compared with NRTI with NNRTI), and current
use of stavudine+lamivudine as compared to tenofovir +
emtricitabine (Table 2).
Prevalence Analysis
Prevalent type 2 diabetes analysis was performed on
12,001 patients at their last follow-up in ICONA. Character-
istics of the patients used in the prevalence analysis are
summarized in Table 1 (right side). HCV antibodies were
detected in 29.3% of 10,611 tested, whereas HCV RNA was
detectable in 75.1% of 1095 tested; CMV IgG were positive
in 84.6% of 7033 tested. Three hundred six patients (2.5%)
had a diagnosis of type 2 diabetes at last follow-up. Factors
associated with prevalent diabetes are summarized in Table 3.
Again, HCV RNA-positive status [adjusted odds ratio, AOR
2.49 (1.08–5.74)] was independently associated with preva-
lent type 2 diabetes, whereas HCV-antibody-positive, HCV
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TABLE 1. Characteristics of Study Patients
Characteristic
Baseline Characteristics of
Patients Used in the Incidence
Analysis (n = 6505)
Characteristics of Patients
at the Time of the Prevalence
Analysis (n = 12,001)
Calendar month median (IQR) June 2002 January 1998–April 2010 March 2003 July 1999–June 2009
Male gender, n (%) 4636 71.3 8980 74.8
Age, median (IQR), yr 36 31–42 41 35–49
Mode of HIV transmission, n (%)
Heterosexual contacts 2624 40.3 4581 38.2
IDU 1788 27.5 3867 32.2
MSM 1730 26.6 2747 22.9
Other/unknown 363 5.6 806 6.7
CDC stage C, n (%) 706 10.8 1681 14.1
BMI category, kg/m2, n (%)
,18 304 4.7 351 2.9
18.5–25.9 3765 57.9 4609 38.4
25–29.9 1109 17.1 1791 14.9
$30 238 3.6 456 3.8
Missing 1089 16.7 4794 39.9
ALT median (IQR), IU/mL 29 19–48 28 19–45
AST median (IQR), IU/mL 27 20–42 25 19–37
Creatinine median (IQR), mg/dL 0.9 0.7–1.0 0.9 0.7–1.0
Triglycerides median (IQR), mg/dL 109 77–157 115 81–172
Total cholesterol median (IQR), mg/dL 165 138–193 179 150–210
Hypertension, n (%) 1116 17.2 2540 21.2
CD4 nadir, median (IQR), cells/mL 380 192–569 238 147–420
CD4 nadir, n (%) in category of cells/mL
0–199, n (%) 1548 23.8 3763 31.4
200–349, n (%) 1187 18.2 3458 28.8
350+, n (%) 3271 50.3 4131 34.4
Missing 499 7.7 645 5.4
HCV status
HCV Ab2 4185 64.3 7505 62.5
HCV Ab+ and HCV-RNA2 170 2.6 273 2.3
HCV Ab+ and HCV-RNA+ 863 13.3 822 6.8
HCV Ab+ and HCVRNA nd 894 13.7 2011 16.8
HCV Ab nd 393 6.1 1390 11.6
HCV genotype,* n (%)
1 362 41.9 197 24.0
2 25 2.9 11 1.3
3 263 30.5 115 14.0
4 90 10.4 52 6.3
Mixed/unknown 129 14.9 447 54.4
HCV RNA load, median (IQR) log10 IU/mL 5.9 5.4–6.3 5.9 5.5–6.4
HBsAg
Positive 330 5.1 554 4.6
Negative 6009 92.4 9827 81.9
Not known 166 2.5 1620 13.5
CMV IgG
Positive 5488 84.4 1085 9.0
Negative 1017 15.6 5948 49.6
Not known 0 0 4968 41.4
Patients initiating ART (Incidence analysis) or on ART
(prevalence analysis)
5442 83.7 7451 62.1
*Among the HCV RNA positives.
ART, antiretroviral therapy; BMI, body mass index; CDC, centers for disease control; CMV, Cytomegalovirus; IDU, injecting drug users; MSM, men having sex with men;
NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.
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RNA-negative status was not. Also, in this analysis, CMV
IgG serology was not associated with diabetes. Other factors
independently associated with prevalent diabetes were older
age, a more recent time from HIV diagnosis, higher BMI, and
current use of zidovudine + lamivudine, didanosine +
stavudine, didanosine + lamivudine or other (uncommon)
NRTI combinations as compared to tenofovir + emtricitabine.
Interestingly, transaminase levels were associated with prev-
alent diabetes at univariate analysis but lost this association in
the adjusted model completely.
DISCUSSION
In this cohort study, we observed how, in HIV-infected
patients, active HCV replication was independently associ-
ated both with incident and prevalent type 2 diabetes.
Interestingly, this association was not observed in HCV-
seropositive individuals without active HCV replication. This
association was independent from several confounders
including ALT or AST in both incident and prevalent
diabetes analysis.
Our findings contribute to resolve the contradictory
observations made in the HIV-positive and HIV-negative
population, where the association between HCV and diabetes
was mostly studied using HCV antibody status as marker of
HCV infection. Indeed, an association was observed in some
studies4,10 but not confirmed in others.11,12 In the HIV-
infected population, approximately 80%–85% of HCV-
antibody-positive patients show a detectable serum HCV
RNA. The proportion of HCV-antibody-positive patients
without active HCV replication is deemed to increase because
of the spread of highly effective HCV eradication therapies
with direct acting antivirals.16 Given the observed association
with active HCV replication but not with simple HCV-
antibody-positive status, our study reinforces the hypothesis
that HCV infection and replication per se and not its
associated behavioral or biological factors are directly
involved in the pathogenesis of type 2 diabetes.
Several biological mechanisms have been hypothesized
through which HCV infection may favor type 2 diabetes.
HCV infection is thought to induce insulin resistance through
multiple mechanisms, involving both the liver and peripheral
tissues.17,18 Some of these mechanisms lead to an increased
production of proinflammatory cytokines (such as TNF alpha
and interleukin 6),19 others result in the induction of liver
steatosis, which is more prevalent in patients infected with
HCV genotype 3.20 In this study, we were unable to detect an
association between a specific HCV genotype, the entity of
HCV replication, and type 2 diabetes. This finding may have
been limited by the dispersion of the different HCV
genotypes in the cohort and the proportion of missing values
which may have reduced the power to detect an association.
With these limitations in mind, our observations may suggest
that the presence of HCV replication and not its entity or type
is associated with diabetes, indicating an indirect pathogenetic
role for HCV.
Other factors associated with type 2 diabetes, male sex,
older age, higher baseline BMI, glucose and triglycerides, and
hypertension are consistent with those found in other cohorts
of HIV-infected and uninfected individuals.21 Interestingly,
we also found that regimens containing d-drugs were
associated with a higher risk of diabetes, consistent with
their higher metabolic impact. Similarly, a higher incidence
was observed for the association of NRTI with unboosted PI,
probably representing older regimens with PI showing a deep-
er impact on insulin resistance.
Our findings have a very strong practical implication.
Indeed, HCV eradication, a goal which is now obtainable in
the majority of HCV/HIV co-infected individuals, may result
in an additional clinical benefit in this population. We found
a 73% (95% CI: 8% to 178%) increase in incidence of
diabetes in individuals with active HCV replication. Given
the overall incidence in our study population, this translates in
an incidence of approximately 1.5 per 100 PY of type 2
diabetes attributable to active HCV replication. Given the
chronicity of type 2 diabetes and its clinical consequences and
assuming that the majority of these cases could be averted by
HCV eradication, HCV treatment in this population may
result in a relevant benefit in terms of both patients and public
health, not only because of the prevention of liver-related
morbidity and mortality.
Another goal of the current study was to explore the
association of latent CMV infection with type 2 diabetes. We
found no association of positive CMV IgG serostatus neither
with incident nor with prevalent type 2 diabetes. This is the
first analysis of this kind in the HIV-infected population and
its results are in contrast with some observation in the elderly
HIV-uninfected population.14 Although CMV-positive seros-
tatus has been associated with increased immune activation in
HIV,13 the absence of any correlation with type 2 diabetes, in
contrast to the observed association with active HCV
replication, suggests that distinct immune-inflammatory
mechanisms are triggered by these 2 very different chronic
viral infections. However, because we could not analyze the
plasma CMV DNA status, our observation does not exclude
the role of active CMV replication in determining the risk
of diabetes.
FIGURE 1. Estimated probability of type 2 diabetes. Kaplan–
Meier method. Baseline was the time of the first available CMV
serology. Patients with pre-baseline diabetes were excluded.
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The results of this study should be interpreted with
caution given its retrospective nature. However, in the
ICONA cohort, this limitation is only partial, given the fact
that patients are enrolled and followed prospectively and that
the diagnosis of clinical events, including diabetes, is
validated by an external monitor using standardized criteria.
In conclusion, in this large observational study, we
found a significant association of active HCV replication with
incident and prevalent type 2 diabetes. This result is
consistent with previous observations in the HCV mono-
infected population and with the hypothesized mechanism by
which HCV may induce liver steatosis and insulin resistance.
TABLE 2. Predictors of Incident Type 2 Diabetes Using a Poisson Regression Analysis
Variable
Univariable Analysis Multivariable Analysis
RR (95% CI) P ARR (95% CI) P
Male gender vs female 1.72 (1.15 to 2.57) 0.009 1.73 (1.41 to 2.12) ,0.001
Age (per 10 yrs increase) 2.05 (1.77 to 2.38) ,0.001 1.06 (1.04 to 1.08) ,0.001
CDC stage C vs A/B 2.30 (1.53 to 3.46) ,0.001 1.67 (0.97 to 2.88) 0.065
BMI at baseline, kg/m2
,18.5 2.35 (0.58 to 9.60) 0.234 0.26 (0.04 to 1.93) 0.189
18.5–24.9 1 1.00
25–29.9 4.98 (1.20 to 20.66) 0.027 2.10 (1.31 to 3.38) 0.002
$30 13.20 (3.08 to 56.68) 0.001 6.47 (3.49 to 12.01) ,0.001
Blood glucose at baseline, mg/dL
,125 1.00 1.00
.125 28.64 (15.72 to 52.17) ,0.001 5.17 (1.95 to 13.71) 0.001
AST at baseline (per 50 U/L higher) 1.00 (1.00 to 1.00) 0.071 1.08 (1.00 to 1.17) 0.057
Current triglycerides (per 100 mg/dL higher) 1.00 (1.00 to 1.00) ,0.001 1.05 (1.12 to 4.50) ,0.001
Current hypertension status 2.35 (1.68 to 3.27) ,0.001 1.85 (1.23 to 2.78) 0.003
CD4 nadir, cells/mL
0–199 1.00 1.00
200–349 0.51 (0.30 to 0.86) 0.012 0.66 (0.35 to 1.22) 0.185
350+ 0.53 (0.36 to 0.77) 0.001 0.67 (0.39 to 1.14) 0.138
HCV infection status at baseline
HCV Ab2 1.00 1.00
HCV Ab+/HCV RNA2 0.17 (0.02 to 1.25) 0.082 0.28 (0.04 to 2.02) 0.206
HCV Ab+/HCV RNA+ 1.25 (0.85 to 1.85) 0.250 1.73 (1.08 to 2.78) 0.023
HCV Ab+/HCV RNA nd 0.70 (80.36 to 1.35) 0.285 0.71 (0.30 to 1.69) 0.439
HCV Ab nd 0.82 (0.38 to 1.78) 0.622 0.86 (0.34 to 2.17) 0.752
HCV genotype 2 vs 1 1.53 (0.20 to 11.88) 0.683
3 vs 1 1.64 (0.73 to 3.66) 0.227
4 vs 1 1.81 (0.63 to 5.21) 0.271
HCV RNA (per 1 log IU/mL higher) 1.10 (0.91 to 1.32) 0.322
HBsAg (positive vs negative) 0.55 (0.20 to 1.49) 0.242
Baseline CMV IgG neg. vs pos. 0.97 (0.62 to 1.52) 0.911 1.11 (0.64 to 1.91) 0.721
Drug classes in the current regimen
NRTI + NNRTI 1.00 1.00
NRTI + PI/r 1.37 (0.82 to 2.28) 0.231 1.15 (0.65 to 2.02) 0.635
NRTI + unboosted PI 2.11 (1.27 to 3.50) 0.004 2.07 (1.17 to 3.68) 0.013
Only NRTI 1.47 (0.81 to 2.66) 0.205 1.38 (0.65 to 2.90) 0.398
Other 1.72 (0.75 to 3.91) 0.198 1.54 (0.61 to 3.87) 0.361
Current NRTI combination
tenofovir + emtricitabine 1.00 1.00
tenofovir + lamivudine 0.26 (0.03 to 1.88) 0.181 0.27 (0.04 to 2.04) 0.205
abacavir + lamivudine 0.97 (0.40 to 2.37) 0.950 1.16 (0.47 to 2.90) 0.749
zidovudine + lamivudine 1.24 (0.73 to 2.12) 0.423 1.07 (0.57 to 2.02) 0.835
stavudine + lamivudine 2.53 (1.39 to 4.59) 0.002 2.52 (1.22 to 5.20) 0.013
stavudine + didanosine 1.18 (0.45 to 3.07) 0.741 1.09 (0.39 to 3.06) 0.872
Variables assayed in the multivariable model include only those associated with P , 0.1 at univariable analysis plus Cytomegalovirus IgG status.
ARR, adjusted relative risk; BMI, body mass index; CDC, centers for disease control; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse
transcriptase inhibitors; PI, protease inhibitors; RR, relative risk.
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TABLE 3. Factors Associated With Prevalent Type 2 Diabetes Using Logistic Regression
Variable
Univariable Analysis Multivariable Analysis
OR (95% CI) P AOR (95% CI) P
Male vs female 1.55 (1.15 to 2.08) 0.004 0.70 (0.40 to 1.21) 0.202
Age (per 10 years increase) 1.32 (1.19 to 1.46) ,0.001 1.04 (1.02 to 1.06) ,0.001
Mode of HIV transmission
Heterosexual 1.00 1.00
IDU 0.57 (0.43 to 0.76) ,0.001 0.90 (0.48 to 1.69) 0.753
MSM 0.78 (0.58 to 1.04) 0.090 0.84 (0.37 to 1.92) 0.684
Other/unknown 0.86 (0.54 to 1.35) 0.511 0.63 (0.24 to 1.64) 0.340
Years from HIV diagnosis (per 1 yr more) 0.89 (0.87 to 0.91) ,0.001 0.95 (0.91 to 0.99) 0.014
CDC stage C vs A/B 1.29 (0.95 to 1.74) 0.099 1.20 (0.64 to 2.23) 0.568
BMI, kg/m2
,18.5 0.58 (0.18 to 1.87) 0.365 NE
18.5–24.9 1.00 1.00
25–29.9 2.15 (1.50 to 3.08) ,0.001 1.12 (0.61 to 2.06) 0.715
$30 6.52 (4.35 to 9.77) ,0.001 3.55 (1.82 to 6.92) ,0.001
ALT per U/L increase 1.00 (1.00 to 1.00) 0.006 1.00 (1.00 to 1.00) 0.920
AST per U/L increase 1.00 (1.00 to 1.00) 0.007 1.00 (1.00 to 1.01) 0.372
Hypertension (present vs absent) 1.81 (1.42 to 2.31) ,0.001 1.09 (0.66 to 1.79) 0.734
CD4 nadir, cells/mL
0–199 1.00 1.00
200–349 0.57 (0.40 to 0.81) 0.002 1.09 (0.61 to 1.95) 0.770
350+ 0.55 (0.39 to 0.77) ,0.001 0.84 (0.42 to 1.67) 0.613
HCV infection status at baseline
HCVAb2 1.00 1.00
HCVAb+ and HCV-RNA2 0.66 (0.21 to 2.09) 0.482 1.33 (0.77 to 6.48) 0.720
HCVAb+ and HCV-RNA+ 2.49 (1.68 to 3.68) ,0.001 2.49 (1.08 to 5.74) 0.032
HCVAb+ and HCVRNA nd 0.99 (0.67 to 1.46) 0.972 0.66 (0.27 to 1.59) 0.354
HCVAb nd 5.27 (4.05 to 6.84) ,0.001 0.63 (0.15 to 2.70) 0.529
HCV genotype 2 vs 1 NE
3 vs 1 0.93 (0.33 to 2.59) 0.891
4 vs 1 1.04 (0.28 to 3.86) 0.959
HCV RNA (per 1 log IU/mL higher) 0.91 (0.66 to 1.24) 0.542
HBsAg (positive vs negative) 0.66 (0.31 to 1.41) 0.283
CMV IgG at baseline
Positive 1.00 1.00
Negative 1.08 (0.71 to 1.66) 0.717 1.02 (0.51 to 2.05) 0.946
Not known 1.35 (1.07 to 1.72) 0.013 0.50 (0.27 to 0.91) 0.024
Current CD4 count (per 100 cell/mL higher) 0.95 (0.90 to 0.99) 0.022 1.04 (0.99 to 1.09) 0.141
Drug classes in the current regimen
NRTI + NNRTI 1.00 1.00
NRTI + PI/r 1.26 (0.79 to 2.03) 0.332 1.29 (0.66 to 2.51) 0.455
NRTI + PI 5.44 (3.40 to 8.72) ,0.001 1.67 (0.73 to 3.81) 0.222
Only NRTI 4.07 (2.32 to 7.16) ,0.001 1.52 (0.52 to 4.48) 0.446
Other 2.24 (0.86 to 5.80) 0.097 2.15 (0.52 to 8.82) 0.287
Current NRTI combination
tenofovir + emtricitabine 1.00 1.00
tenofovir + lamivudine 1.14 (0.27 to 4.78) 0.858 1.49 (0.19 to 11.65) 0.704
abacavir + lamivudine 0.83 (0.35 to 1.98) 0.676 0.99 (0.34 to 2.82) 0.978
zidovudine + lamivudine 4.26 (2.63 to 6.92) ,0.001 3.34 (1.55 to 7.20) 0.002
stavudine + lamivudine 7.10 (4.00 to 12.60) ,0.001 3.02 (0.92 to 9.87) 0.068
stavudine + didanosine 6.91 (3.14 to 15.22) ,0.001 5.58 (1.51 to 20.71) 0.010
didanosine + lamivudine 6.81 (2.35 to 19.72) ,0.001 8.33 (1.86 to 37.22) 0.006
other 3.67 (2.27 to 5.96) ,0.001 2.78 (1.09 to 7.12) 0.033
Variables assayed in the multivariable model included only those associated with P , 0.1 at univariable analysis.
AOR, adjusted odds ratio; BMI, body mass index; CDC, centers for disease control; NE, not estimable; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside
reverse transcriptase inhibitors; OR, odds ratio; PI, protease inhibitors.
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Future studies should aim to determine whether HCV
eradication with antiviral therapy may be able to revert this
increased risk.
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